Sirolimus & Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor HCT

Not Recruiting

Trial ID: NCT00350181

Purpose

GVHD prophylaxis of sirolimus and mycophenolate mofetil for patients undergoing matched related allogeneic transplant for acute and chronic leukemia, MDS, high risk NHL and HL

Official Title

Sirolimus and Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor Hematopoietic Cell Transplantation

Stanford Investigator(s)

Laura Johnston
Laura Johnston

Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)

Robert Lowsky
Robert Lowsky

Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)

Robert Negrin
Robert Negrin

Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)

Sally Arai
Sally Arai

Associate Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)

Judith Shizuru
Judith Shizuru

Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy) and of Pediatrics (Stem Cell Transplantation)

Eligibility


Inclusion Criteria:

   - Disease Categories: (one of the following)

      - AML, age 2 - 60 years beyond 2nd remission or relapsed/refractory disease

      - AML, age 51-60 years of age, in first or subsequent remission or
      relapsed/refractory disease

      - AML with multilineage dysplasia

      - ALL, age 2 - 60 years beyond 2nd remission or relapsed/refractory disease

      - ALL, age 51 - 60 years in first or subsequent remission or relapsed/refractory
      disease

      - CML Beyond 2nd chronic phase or in blast crisis

      - MDS; Includes World Health Organization classifications of refractory anemia with
      excess blasts-1 (RAEB-1), RAEB-2 and therapy-related MDS

      - Myeloproliferative disorders; MDS with poor long-term survival including myeloid
      metaplasia and myelofibrosis

      - High risk NHL in first remission

      - Relapsed or refractory NHL

      - HL beyond first remission

   - Males and females of any ethnic background 2 - 60 years of age

   - Karnofsky Performance Status ≥ 70% or Lansky performance status > 70% for patients <
   16 years of age.

   - Matched related donor identified: 6/6 HLA-A, B and DRB1

   - Willingness to take oral medications during the transplantation period

   - Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

   - Prior myeloablative allogeneic or autologous HCT

   - HIV infection

   - Pregnant

   - Lactating females

   - Evidence of uncontrolled active infection

   - Organ Dysfunction:

   - Serum creatinine > 1.5 mg/dL or 24 hour creatinine clearance < 50 ml/min

   - Direct bilirubin, ALT or AST > 2 x ULN

   - In adults DLCO < 60% predicted and in children room air oxygen saturation < 92%

   - In adults, left ventricular ejection fraction < 45% and in children, shortening
   fraction < 26%

   - Fasting Cholesterol > 300 mg/dL or Triglycerides > 300 mg/dL while on lipid-lowering
   agents.

   - Patients receiving investigational drugs unless cleared by the PI.

   - Patients with prior malignancies except basal cell carcinoma or treated carcinoma
   in-situ.

   - Cancer treated with curative intent > 5 years will be allowed.

   - Cancer treated with curative intent ≤ 5 years will not be allowed with PI approval.

Intervention(s):

drug: Sirolimus

drug: MMF

drug: BCNU

drug: VP-16

drug: CY

drug: FTBI

drug: BU

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
BMT Referrals
6507230822

New Trial Alerts

Receive email alerts when trials open to patients.